RADNOR, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage...
RADNOR, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage...
RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage...
– Topline data from confirmatory Launch-HTN trial expected in 2H 2025 – – Topline data from ongoing...
– New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence...
RADNOR, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage...
– On track to initiate planned Phase 3 pivotal Launch-HTN trial of lorundrostat to treat patients with...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.